Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
A case of psoriasis successfully treated by extracorporeal photopheresis during COVID-19 pandemic

Pelin Esme a,*, Sema Nur Coban a, Bilge Ugur b, Meltem Aylı b, Ercan Caliskan a

a Departments of Dermatology and Venerology, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey
b Departments of Hematology, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey

1. Introduction

Psoriasis is a chronic inflammatory skin disease that is characterized by well-demarcated erythematous plaques with a silver scale. Although many new and emerging therapeutic agents are often sufficient to control the disease, there is still a need for alternative treatment options in challenging cases. Extracorporeal photopheresis (ECP) has been applied to many T-cell-mediated diseases to restore immune homeostasis and treat psoriasis effectively. In this paper, we present a psoriasis patient who did not respond to methotrexate, narrowband ultraviolet B, or acitretin. Because of a diagnosis of non-Hodgkin lymphoma, the patient had contraindications for cyclosporine, fumaric acid esters, and biologics but achieved remission with a total of 12 sessions of ECP in two and a half months. Although exacerbation was recorded after polymerase chain reaction (PCR) confirmed coronavirus 2019 (COVID-19) disease infection at the end of the first month, scores from the psoriasis area severity index (PASI) and dermatological life quality index (DLQI) were regressed significantly within two and a half months. ECP seems to provide an effective and rapid response for psoriasis and should be considered for psoriasis patients who fail to respond or have contraindications to existing treatments.
2. Case presentation

A 51-year-old man was referred to our outpatient clinic with a diagnosis of recalcitrant and severe psoriasis. The patient was diagnosed with psoriasis and non-Hodgkin lymphoma following histopathological confirmation four and three years ago, respectively. He also had psoriatic arthritis and asthma. Dermatological examination of the patient revealed results that were consistent with thick, scaly plaques on the elbows, knees, dorsum of the feet and hands, posterior and anterior trunk. There were prominent signs of psoriatic nail involvement on fingers and toes. Owing to the severity of psoriasis, topical agents alone were not considered. The patient did not obtain any additional benefit from 25 mg/day of acitretin. Methotrexate was administered two separate times but had to be stopped owing to severe liver impairment. The patient was unresponsive to long sessions (62 sessions) of narrow-band ultraviolet B (UVB). Because patients with a history of systemic malignancy in the last five years should avoid cyclosporine and biological agents, fumaric acid was considered for off-label use. However, it was not approved owing to the risk of progression of non-Hodgkin lymphoma.

ECP was considered for the patient in the present research in order to avoid systemic side effects during the selective restoration of the immune system. The central venous access, considered a clean skin area from the psoriasis plaques, was used with a double-needle and a total blood volume of 1500 mL. To prevent occlusion of the catheters, heparin was administered in an amount (approximately 1.2 and 1.4 mL) to fill the catheter lumens at the end of each treatment session. The patient had received a total of 12 ECP sessions within 2.5 months, as depicted in Fig. 1. However, the ECP had to be interrupted for 15 days at the end of the first month because he had coronavirus disease 2019 (COVID-19) disease confirmed by polymerase chain reaction. The patient described only flu-like symptoms and did not have severe symptoms that required hospitalization. While exacerbation was recorded during this period, the patient improved significantly after two and a half months on the basis of two objective scores. The PASI score, which is calculated for the extent of involved body surface area and the intensity of redness, scaling, and plaque thickness, was significantly regressed from 17.5 to 2.8 (Figs. 2 and 3). The dermatological life quality index (DLQI), which is the tool most frequently used to measure the impact of skin disease on the quality of life, improved from 19 to 6. Considerable improvement was also observed in psoriatic nail findings, such as distal onycholysis, oil spots, and splinter hemorrhage, according to the records of dermatoscopic photographs taken two and a half months apart (Fig. 4). The patient tolerated ECP well without any evidence of side effects.

No other patients had symptoms or signs of COVID-19 during ECP procedures thanks possibly to strict hospital measures (increased sanitization intervals, periodic ventilation, and disinfection of rooms, adequate social distance between treatment beds, use of masks and hand sanitizers by hospital staff and patients, temperature monitoring before and after treatment sessions) against COVID-19. The PCR test was taken on the 14th day according to the national guideline of the Ministry of Health (Turkey). After confirmation of PCR negativity and symptom resolution, treatment was re-started on the 15th day.

3. Discussion

Psoriasis is a chronic immune-mediated skin disease with important impacts on patients’ quality of life. It is much more than a skin disease. Several medical comorbidities, especially joint involvement, may accompany psoriasis in patients [7]. While advances in pathophysiology continue to increase, as of today, the pathogenesis of psoriasis can be summarized as alterations or dysregulation in innate and acquired immune response. Interferon-alpha, tumor necrosis factor-alpha, interleukin 12 and 23, produced by plasmacytoid dendritic cells, and myeloid dendritic cells play a central role in the disease pathogenesis but also has led to a tremendous improvement in therapeutic efficacy through selective blockade [7,8]. Although it is known that CD4-positive T cells and less prominently CD8-positive T cells are observed in inflammatory infiltrates, the discovery of T helper 17 cells has led to important insights in this era [9].

ECP has been used to treat cutaneous T-cell lymphoma, graft versus host disease, transplant rejection, and many autoimmune diseases for more than 25 years [5,6]. It is thought to mimic the physiological process of peripheral tolerance through the immature dendritic cells and apoptotic leukocytes—the two key elements of peripheral immune tolerance—also suppressing effector T cell responses and upregulating T regulator cells, which is the 3rd key player of peripheral immune tolerance [5]. Although it restores immunotolerance, it does not cause an increase in the risk of infection or malignancy as in conventional immunosuppressive therapies. Therefore, it has been used to treat a broad spectrum of autoimmune dermatological diseases, including scleroderma, systemic lupus erythematosus, atopic dermatitis, epidermolysis bullosa acquisita, cutaneous mucinosis, lichen planus, pemphigus, and psoriasis [5,6,10]. In a study conducted with a group of eight patients with psoriasis and seronegative arthritis, it was reported that the effectiveness of treatment lasted more than one year in half of the patients who responded very well [11]. In addition to selective immunosuppression, the long duration of the therapeutic effect after cessation of the treatment makes ECP a unique alternative in autoimmune diseases. [5].

Several months, usually five–six months, are required to observe the maximal clinical outcomes in classical autoimmune diseases with ECP. While in a case series of four psoriasis patients—a period of 6–13 months was reported as a required period for clinical efficacy (10)—we observed an almost complete significant clearance of psoriatic plaques and marked improvement on nails at the end of the two and a half months of ECP treatment.

4. Conclusion

Although ECP is time-consuming and only available in specialized centers, it has many advantages for autoimmune dermatological diseases, including psoriasis. Our experience leads us to recommend ECP to manage challenging psoriasis cases.
Contributorship Statement: PE for conception or design of the work; the acquisition, analysis, interpretation of data for the work, and approval of the final version of the manuscript; SC for conception or design of the work; the acquisition, analysis, interpretation of data for the work; BU for conception or design of the work; the acquisition, analysis, interpretation of data for the work, MA for conception or design of the work; the acquisition, analysis, interpretation of data for the work, EC for conception or design of the work; the acquisition, analysis, drafting the work and revising it critically for important intellectual content.

Data availability statement

Data available on request from the authors

CRediT authorship contribution statement

Pelin Esme for conception or design of the work; the acquisition, analysis, interpretation of data for the work, and approval of the final version of the manuscript. Semanur Coban for conception or design of the work; the acquisition, analysis, interpretation of data for the work. Bilge Ugur for conception or design of the work; the acquisition, analysis, interpretation of data for the work. Meltem Ayli for conception or design of the work; the acquisition, analysis, drafting the work and revising it critically for important intellectual content.
Financial support

None.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Publication status

On behalf of all the authors that the work has not been published and is not being considered for publication elsewhere.

Declaration of Competing Interest

The authors report no declarations of interest.

Acknowledgements

None.

References

[1] Menter A, Gelfand JM, Conn C, Armstrong AW, Cordoro KM, Davis DM, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol 2020;82(6):1445–86.
[2] Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010;62(1):114–35.
[3] Shibata E, Chaimani A, Garcia-Dolce I, De G, Huc C, Mazaud C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017;2212(12):CD011535.
[4] Ling YL, Huang X, Mitri G, Lovelace B, Pham A, Knobler R, et al. Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010–2015. J Dermatol Treat 2020;31(1):91–8.
[5] Adamski J, Kinard T, Ipe T, Cooling L. Extracorporeal photopheresis for the treatment of autoimmune diseases. Transfus Apher Sci 2015;52(2):171–82.
[6] Andreas-Ullrich H. Miscellaneous indications for extracorporeal photochemotherapy (ECP). Transfus Apher Sci 2014;50(3):363–9.
[7] Wollenberg A, Wagner M, Günther S, Towarowski A, Tuma E, Moderer M, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002;119(5):1096–102.
[8] Hansel A, Günther C, Ingwersen J, Starke J, Schnitz M, Bachmann M, Meurer M, Rieber EP, Schakol K. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. J Allergy Clin Immunol 2011;127(3):787–94, e1–9.
[9] Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009;129(6):1339–50.
[10] Vanderheiden EC, Bigler RD, Rogers TJ, Kadin ME, Griffin TD. Effect of extracorporeal photopheresis on selected immunologic parameters in psoriasis vulgaris. Yale J Biol Med 1989;62(6):653–64.
[11] Vahlquist C, Larsson M, Ernerudh J, Berlin G, Skogh T, Vahlquist A. Treatment of psoriatic arthritis with extracorporeal photopherotherapy and conventional psorales-ultraviolet A irradiation. Arthritis Rheum 1996;39(9):1519–23.

Fig. 4. Regression of the psoriatic nail findings, such as distal onycholysis, oil spots, and splinter hemorrhage, are shown here (top row: pre-treatment photos, bottom row: two and a half months after ECP).